Treatment of ankylosing spondylitis

被引：23

作者：

Sari, Ismail ^{[1
]}

Ozturk, Mehmet Akif ^{[2
]}

Akkoc, Nurullah ^{[1
]}

机构：

[1] Dokuz Eylul Univ, Fac Med, Div Rheumatol & Immunol, Dept Internal Med, Izmir, Turkey

[2] Gazi Univ, Fac Med, Div Rheumatol, Dept Internal Med, Ankara, Turkey

来源：

TURKISH JOURNAL OF MEDICAL SCIENCES | 2015年 / 45卷 / 02期

关键词：

Ankylosing spondylitis; treatment; nonsteroid antiinflammatory drugs; disease modifying antirheumatic drugs; corticosteroids; anti-TNF agents; NONSTEROIDAL ANTIINFLAMMATORY DRUGS; PLACEBO-CONTROLLED TRIAL; NECROSIS-FACTOR-ALPHA; METHYLPREDNISOLONE PULSE THERAPY; RANDOMIZED CONTROLLED-TRIAL; GUIDED CORTICOSTEROID INJECTION; UPPER GASTROINTESTINAL TOXICITY; REDUCES SPINAL INFLAMMATION; LOW-DOSE INFLIXIMAB; ETANERCEPT; 50; MG;

D O I：

10.3906/sag-1401-79

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Ankylosing spondylitis is a chronic, inflammatory, rheumatic disease that can reduce the quality of life and increase the risk of disability and mortality. It also causes direct and indirect economic losses due to health expenses and as a result of workforce loss. Management of this disease consists of pharmacological and nonpharmacological modalities. Until recently, pharmacological treatment options have been very limited. However, development of novel biological drugs revolutionized the management of this disease. The aim of this review article is to present an updated overview of the pharmacologic treatment of ankylosing spondylitis. Nonpharmacological treatment modalities including physiotherapy and exercise are only briefly mentioned and surgical treatment is not discussed.

引用

页码：416 / 430

页数：15

共 157 条

[1] Ankylosing spondylitis and symptom-modifying vs disease-modifying therapy [J].

Akkoc, Nurullah ;

van der Linden, Sjef ;

Khan, Muhammad Asim .

BEST PRACTICE & RESEARCH IN CLINICAL RHEUMATOLOGY, 2006, 20 (03) :539-557

[2]

Altan L, 2001, SCAND J RHEUMATOL, V30, P255

[3]

AMOR B, 1995, RHEUM DIS CLIN N AM, V21, P117

[4]

AMOR B, 1995, REV RHUM, V62, P10

[5]

[Anonymous], 2013, COCHRANE DATABASE SY

[6] Anti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled trial [J].

Baeten, Dominique ;

Baraliakos, Xenofon ;

Braun, Juergen ;

Sieper, Joachim ;

Emery, Paul ;

van der Heijde, Desiree ;

McInnes, Iain ;

van Laar, Jacob M. ;

Landewe, Robert ;

Wordsworth, Paul ;

Wollenhaupt, Juergen ;

Kellner, Herbert ;

Paramarta, Jacqueline ;

Wei, Jiawei ;

Brachat, Arndt ;

Bek, Stephan ;

Laurent, Didier ;

Li, Yali ;

Wang, Ying A. ;

Bertolino, Arthur P. ;

Gsteiger, Sandro ;

Wright, Andrew M. ;

Hueber, Wolfgang .

LANCET, 2013, 382 (9906) :1705-1713

[7] Clinical response to discontinuation of anti-TNF therapy in patients with ankylosing spondylitis after 3 years of continuous treatment with infliximab [J].

Baraliakos, X ;

Listing, J ;

Brandt, J ;

Rudwaleit, M ;

Sieper, J ;

Braun, J .

ARTHRITIS RESEARCH & THERAPY, 2005, 7 (03) :R439-R444

[8] Magnetic resonance imaging examinations of the spine in patients with Ankylosing spondylitis before and after therapy with the tumor necrosis factor α receptor fusion protein etanercept [J].

Baraliakos, X ;

Davis, J ;

Tsuji, W ;

Braun, J .

ARTHRITIS AND RHEUMATISM, 2005, 52 (04) :1216-1223

[9]

Baraliakos X, 2007, J RHEUMATOL, V34, P510

[10] Long-term outcome of patients with active ankylosing spondylitis with etanercept-sustained efficacy and safety after seven years [J].

Baraliakos, Xenofon ;

Haibel, Hildrun ;

Fritz, Claudia ;

Listing, Joachim ;

Heldmann, Frank ;

Braun, Juergen ;

Sieper, Joachim .

ARTHRITIS RESEARCH & THERAPY, 2013, 15 (03)

← 1 2 3 4 5 6 7 8 9 10 →